Gapping up
In reaction to strong earnings/guidance:
- EOLS +9.8%, NERV +7.1%, KPTI +6.9%, RACE +6%, SOHU +4.9%, BHC +3.7%, S +2.7%, SUP +2.3%, SPNS +1.4%, BRK.B +1%, FE +0.7%
M&A news:
- WMGI +31.5% (to be acquired by Stryker (SYK) for $30.75 per share in cash)
Select financial related names showing strength:
- DB +3.2%, SAN +2.2%, BBVA +2.1%, LYG +1.7%, MS +1.4%, HSBC +1.3%
Select oil/gas related names showing strength:
- SWN +3.8%, WLL +2.7%, RDS.A +1.8%, BP +1.6%, SLB +1.6%, HAL +1.5%, XOM +0.8%, MRO +0.6%
Other news:
- RDHL +29.3% (receives FDA approval for Talicia delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults)
- NIO +8.6% (provides October 2019 update -- delivered 2,526 vehicles in October )
- GPRO +1.8% (continued strength)
- ANET +1.7% (slight rebound from last week's earnings)
Analyst comments:
- USM +4.8% (upgraded to Overweight from Neutral at JP Morgan)
- FLL +4.6% (upgraded to Outperform from Neutral at Macquarie)
- MRVL +4% (upgraded to Outperform from Market Perform at Wells Fargo)
- TDS +3.3% (upgraded to Overweight from Neutral at JP Morgan)
- BB +2.7% (upgraded to Neutral from Underperform at BofA/Merrill Lynch)
- BLUE +2.6% (upgraded to Outperform from Neutral at Wedbush)
- DOCU +1.9% (initiated with an Outperform at Evercore ISI)
- HTGC +1.3% (upgraded to Outperform from Market Perform at Wells Fargo)